drugset / Trial / NCT02121717
Study of Chiglitazar Compare With Placebo in Type 2 Diabetes Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this study is to evaluate the efficacy and safety of Chiglitazar, compare with placebo.
Timeline
- Start
- 2014-06
- Primary completion
- 2017-11
- Completion
- 2017-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Chiglitazar | Unknown | 32 mg | Oral |
| Subject | Chiglitazar | Unknown | 48 mg | Oral |